Outcome of specific chemotherapy and total body irradiation as conditioning with post transplant chemotherapy in Haploidentical Stem Cell transplant in blood cancer patients

Outcome of ThioTEPA-Flu-Cy-TBI conditioning with PTCy in Haploidentical Stem Cell transplant in Leukemia and Myelodysplastic syndrome patients - nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/055832

Enrollment

Registered

2023-07-28

Start date

Unknown

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C96Z- Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue

Interventions

Intervention1: Drugs (chemotherapy) & radiation: Thiotepa5 mg/kg (day-7), fludarabine 30 mg/m2 (Day-6 to day-2), cyclophosphamide14.5mg/kg (Day-6 & day-5) & TBI 200-400 cGy (day-1) will be used as con

Eligibility

Inclusion criteria

Inclusion criteria: any sex , age 5 yrs to 50 yrs , acute leukemia & MDS in remission

Exclusion criteria

Exclusion criteria: severe co-morbidity & transplant ineligibility

Design outcomes

Primary

Measure	Time frame
Non Relapse Mortality including transplant related mortality (TRM) & infection rate, GVHD both acute & chronic, graft failure rate, chimerism, relapseTimepoint: 0,1,3,6 & 12 months	—

Secondary

Measure	Time frame
Progression Free Survival(PFS) , Disease Free Survival (DFS), Over all Survival (OS)Timepoint: 1 & 2 yrs	—

Countries

India

Contacts

Public Contactsandeep saha

Nilratan Sircar Medical College Kolkata

drsandeepsaha2007@gmail.com9830268507

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026